Straits Times Index
3,292.69 +10.64 (+0.32%) Nikkei
38,405.66 +470.90 (+1.24%) Hang Seng
17,763.03 +16.12 (+0.09%) FTSE 100
8,144.13 -2.90 (-0.04%) Bitcoin USD
60,089.97 -2,772.11 (-4.41%) CMC Crypto 200
1,284.86 -54.20 (-4.05%)
AMGN Jan 2025 270.000 put
| Previous close | 23.70 |
| Open | 21.88 |
| Bid | 21.80 |
| Ask | 22.30 |
| Strike | 270.00 |
| Expiry date | 2025-01-17 |
| Day's range | 21.83 - 22.10 |
| Contract range | N/A |
| Volume | |
| Open interest | 2.08k |
BenzingaSandoz Settles Patent Dispute With Amgen Related To Bone Disorder Drug Denosumab
Generic and biosimilar manufacturer Sandoz AG (OTC:SDZNY) (OTC:SDZXF) reached an agreement on Tuesday with Amgen Inc (NASDAQ:AMGN) to resolve all patent litigation related to its U.S. denosumab biosimilars. Sandoz said in a statement that the agreement clears the way for the launch of denosumab biosimilars Jubbonti and Wyost on May 31, 2025, or earlier under certain circumstances. “The terms of the agreement will not impact our previously disclosed 2024 guidance,” Sandoz said. Sandoz received FD
ZacksWill These 5 Drug/Biotech Stocks Beat Q1 Earnings Forecast?
Let's look at five large-cap pharma/biotech companies slated to release quarterly results this week.
- Reuters
Sandoz reaches agreement with Amgen over patent dispute
Swiss generic and biosimilar manufacturer Sandoz said on Tuesday it had reached an agreement with U.S. drugmaker Amgen resolving all patent litigation related to its U.S. denosumab biosimilars. The agreement clears the way for the launch of denosumab biosimilars Jubbonti and Wyost on May 31, 2025, or earlier under certain circumstances, Sandoz said in a statement. "The terms of the agreement will not impact our previously disclosed 2024 guidance," Sandoz said.
